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THE development of resistance to chemotherapeutic agents is a familiar
phenomenon in the investigation and treatment of most diseases of infective
origin. It is probable that the production of a refractory state is, as yet, an
invariable result in the chemical treatment ofthose few cases ofmahgnant disease
which respond satisfactorily in the first instance.
The appearance ofresistance tospecific chemical inhibitors has beenrecognised
and investi ated in some kinds of mouse leukaemia (Burchenal, Robinson,
Johnston and Kushida, 1950; Law, 1952a, 1952b) but so far it appears that no
convincing demonstration of this important phenomenon has been made in sofid
animal tumours.
This communication records the development of a persistent refractory state
in the Walker careinosarcoma after treatment with triethylene melamine J),
to which substance the tumour is normaRy very sensitive; the resistant state is
also shown to extend to two related substances, II and III.
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MATERIALS AND METHODS.
Animal,&-Rats of an American Wistar strain werc, used, maintained on a
cube dietsupphedbythe North EasternAgricultureSociety. Duringexperiments each animal was allowed 15 g. daily.
Tumour.-The Walker carcinosarcoma was originally obtained from the
Biological Laboratories of Imperial Chemical Industries. It was easily adapted
to these animals and was maintained by subcutaneous dorsal transplantation into young adult rats (I10-140 g.).
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Assessment of chemotherapeutic potency.-UsuaRy groups of ton animals
(equal numbers of each sex) were used as controls and similar groups were given
daily doses of the drug by theintraperitoneal route, with a double dose on Satur-
day. Exceptwherestated,dosage was commenced 4-5days aftertransplantation.
The drug was dissolved in water and kept in the refrigerator, the solution being
replacecl every few days. Daily inspection of the tumour site was made and the
subsequent growth of the neoplasm estimated by palpation using an arbitrary
scale ofmeasurement ofits sizeiDrelation to the bulk ofthe animal. The animals
were killed 1.0-14 days after implantation and the tumours dissected out and
weighed. The decision to terminate an experiment was governed by the rate of
growth of the tumour in the control series of animals, which varied somewbat
in. different experiments. The effect of treatment was measured by comparing
the mean tumour weights in coDtrol and treated groups and use was also made
of the formula suggested by Walpole (1951), which makes allowance foe those
animals offering undue resistance to the growth of the tumouir.
RESULTS.
Fig. I represents the collected results of the main series of experiments. In
the first ofthese, three groups of ten animals were transplanted with the Walker
tumour. Ten were used as controls, ten received triethylene melamine, 0-1
mg./kg. daily, aDd the remainder received twice this dose. Table I shows the
result ofthis experiment on the group receiving the lower dose level ; the treated
tumours were completely inhibited. The ten animals receiving the higher dose
level were not kflled, but drug treatment was discontinued aftereightCODsecutive
daily doses. SmaR nodules persisted in the majority of these animals without
change for about 2 weeks, after whicb tumours began to grow; they were well
developed in 70 per cent ofthe group 1 month after cessation of treatment. One
TABLEI.-Inhibitory Effect of Triethylenemelamine (0-I mg.lkg. daily, ip.) on the
Walker Carcinosarcoma.
Controls. Treated.
Number of anixnals 10 10
Treatment None 8 doses comrnencing
2nd day
Day tetminated 12 12
Number surviving 10 10
Tumour weights (g.) 17 8 0.5 0-2
12 4 0.5 0-2
9 0 0-4 0.1
9 0 0-3 0.0
9 0 0-2 0.0
of the tumours was selected at random, transplanted as before, and subjected
to a second course of treatment (Fig. 1). This time, growth occurred in spite of
administration of the drug and after 13 days the experiment was terminated.
A subsidiary transplant was made from one of the treated tumours and a group
often animalscarryingtheneoplasmagainexposed to the action ofthecompound.
The development of tumours was not markedly depressed compared with the
control series and iD the next experiment one of these treated tumours was once
moresubjected to a repetition of the above procedure (Fig. 1, fourth treatment).
From this time (Fig. 1,
" 32 weeks ") one of these tumours (the derived tumour)338 H. JACKSON
has been maintainedroutinely by transplantation at intervals of about 2 weeks-
in aR about 50 such transferences have since been carried out. From time to
time the sensitivity -of the tumour to triethylene melamine was tested (Fig. 1)
The continued refractory behaviour of the derived tumour compared with the
original Walker tumour is clearly evident. This resistance to further treatment
shown by such tumours has been confirmed. Thus in another experiment a
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1
:1-d Treated Untreated Treated
i -1 t I
2
I
iecond course
ofT.E.M.
ifter8weeks)
I
3
I
Third course
(10weeks)
I I I
4
I I
Fourth course (12weeks)
5 Sensitivitytest
- - -.- - - (32weeki)
i ---I i I
6A m
I
Sensitivi test
(56we )
II I
I I
6B
I
0
I
I
Phosphommide test(96weeks)
n i
7 a
I
Sensitivity test (60weeks)
FIG. I.-Arepresentationofthedevelopment oftheresistantvarietyfromtheoriginal sensitive
Walkercarcinosarcoma,foRo-wing treatment withtriethylene malamin (T.E.M.). The black
squares are drawn to scale and represent the mean weight of tiimours at the end of an
experiment. Experixnent I showstheeffect ofthedrug(O
- I mg./kg.) on the Walker tumour.
Theinhibited tumourslatergrow, andExperixnent-8 2, 3, 4 and 5 show thatrepeated exposure to the drug has little effect on the gro'wth of the derived tumour ; also that there appears to be no increase in resistance with successive treatments. AfterExperiment 5, the derived
tumour wa-s maintained by transplantation, with occasional tests for susceptibility to the
ethyleneimine (Experiinents 6A and 7). Experiment 6B represents the result of a testusing thediethylenephosphoramide JI) referred to in the text. The control series in the left hand
column illustrate the continued susceptibility of the original Walker tiimour. In between
the experiments referred to above, the resistant tumour was maintained by transplantation about every 10th day.WALKER CARCINOSARCOMA RESISTANCE TO TRIETHYLENE MELAMINE 339
similar tumour (after six intermediate transplants) was tested for sensitivity to
triethylene melamine. The treated animals receivecl 6 daily doses of the drug
(0-2 mg./kg., commencing the 3rd day after transplantation) and the experiment
was terminated on the 12th day.
Untreated animal,8.-Tumour weights (g.) 30, 25, 15, 15, 11.
Treated animal,8.-Tumour weights (g.) 15, 14, 14, 13, 10, 9, 8) 41 3) 2.
The resistance shown by this tumour was of similar magnitude to that shown
by the tumour referred to in Fig. I and it seems reasonable to suppose that the
same applies to all such tumours developing from inhibited nodules.
When drug treatment was commenced 3-5 days after transplantation, both
the sensitive Walker tumour and its refractory derivative were always actively
growing. The former invariably began to regress within 24-48 hr. of the first
dose, whilst the latter continued to grow. When treatment with triethylene
melainine was 'commenced 24 hr. after implantation of the tumour, complete
inhibition oftheoriginal Walker tumour resulted as wasexpected. The compara-
tive tumour weights from this experiment, terminated after 7 daily doses were:
Control&-20, 16, 15) 141 14. 13) 13) 12) 12. 6, (g.).
Treated.-The largest nodule was 300 mg., including a considerable proportion
of necrotic tissue.
The nine animalsremaining in the treated group were kept and tumours began
to grow 2-3 weeks later. Five weeks from the date of termination of treatment
the experiment was concluded and the tumour weights were as follows:
53. 25. 15) 15. 4) 3. 2) 0) 0
The derived tumour, in aparallelexperiment, was also treated with the samedrug
for the same ti'me, commencmg 24 hr. afterimplantation. It developed much as
usual, although not at the same rate as in untreated controls:
Untreated animal,8.-Tumour weights (g.) 24, 22, 20, 20, 191 19) 18Y 10) 7.
Treated animal8.-Tumour weights (_.) 15, 11, 10, 9, 7, 4, 4) 3 1 0.5. 9 I )
Thus even early treatment before the tumour had established itself in the
host animal, failed to eliminate those cells of the original Walker tumour which
later develop into therefractory tumour. Suchearly treatment was also without
effect on thegrowth ofthe resistant tumour, compared withdelayingdrug admini-
stration until the graft was well established (3-5 days).
By way of comparison, Table 11 iRustrates the effect oftriethylene melamine
(0-2 mg./kg.) on the growth of a lymphosarcoma in the same strain of rat.
Tumours grew well in treated animals although some inhibitory effect is apparent
from the final data.
Table III shows the
" inhibitory index
" calculated for various experiments.
Inhibition of the original Walker tumour by the three ethyleneimines referred
to was always virtually complete-it is in fact greater than the results indicate,
for the nodule always contained a variable amount of material other than tumour
tissue. Thegrowth ofthe derived tumour was affected to areasonably consistent
extent by triethylene melamine, comparable to that observed with the lympho-
sarcoma.
The subsequent development of inhibited Walker tumour nodules has been
repeatedly confirmed. Surprisingly, growth was found to occur after a similar
latentperiod inthemajority ofanimals eventhough drug treatment was continued340 H. JACKSON
TABLE II.-Effect of Triethylene Melamine (0-2 mg.lkg. daily, i.p.) on the, Growth
of a LymphO8arcoma.
The degree of inhibitiOD is comparable to that caused iD the resistant
form ofthe Walker tumour. How far this depreSSiOD ofgrowth is related
to the systemic toxicity of the drug on the host animals is not known.
Controls. Treated.
Number of animals 8 10
Treatment None 6 doses commencing
4th day
Number surviving 8 10
Day terminated 13 13
Tumour weights (g.) 37 22 20 9
32 2 13 9
32 0 I 1 4
27 10 1
22 10 I
TABLE III.-Inhibitory Effect of Triethylene Melamine (T.E.M.), Triethylene,
Pho8phoramide, (T.E.P.A.) and a Diethyleneimino-compound (Conipound II)
on the CTrowth of the Walker Carcino8arcoma and the derived (Re8i8tant) form
o thi8 Tumour. f
The
" inhibitory index is based on the formula given by Walpole
(195i), namely:
Inhibitory Index (M50 controls M50 treated) x 100 (M.50 controls)
where M-50 refers to the n heaviest tumours out of any group of2..
Inhibitory
Treatment Day index
Tumour. Drug. (doses). terminated. per (cent).
Original Walker T.E.M. 8 12 98
31 . 9 11 119 8 13 98
51.9 9 51 5 13 95
515- T.E.P.A. 6 I I 96
91, Compound II 8 13 99
Derived Walker T.E.M. 8 13 55
9 9 9 9 9 10 14 53
11 5- 9 9 9 14 34
5-9 6 10 57
9 8 13 57
5 II 18
T.E.P.A. 6 11 44
Compound II 8 13 30
throughout at the same rate. AD example ofthis is shown iD TableIV, from wbich
it is evident that tumoursdeveloped in 8-10 animalsfollowing the usualinbibitory
IOUs g it proceeded rapidly period ofnearly 3 weeks. Once obv' TOwth commenced,
and then slowed quite markedly. In spite of the prolonged treatment in which
31 doses were given, there were no deaths which could be directly attributed to
the effect of the drug. This faflure of continued treatment to maintain the state
of inhibition iD the tumour has also been confirmecl in other experiments.
The contrast insusceptibihty between theoriginal and derived Walker tumours
to the triazine, has also been found. to extend to the two other ethyleneimines, II
and III (Tables III and V). The resistant phenomenon seems therefore to beWALKER CARClNOSARCOMA RESISTANCE TO TRIETHYLENE MELAMINE 341
TABLEIV.-EffectofContinued TreatmentofRat8bearingImplanted Walker Tumour
with Triethylene Melamine (0-2 mg.lkg.).
Administration of the drug was started on the 4th day with the result
that existing tumours regressed and remained inhibited. After a latent
period of nearly 3 weeks, tumours began to grow in spite of continued
exposure to thedrug. Inall, 31 doses ofthe compound were givert. One
animal was killed on Day 27, when it was found that the tumour had
penetrated the abdominal wall and spread vv-idely through the retro-
peritoneal space. and mesenteries. The left kidney had been invaded and
the pancreas partially destroyed. One animal died earlv on in the treat-
ment.
Number of animals showing
Days after No tumour
transplantation. growth. Nodule. Growth.
9 9
13 1 8
20 1 2 6
23 1 1 6
28 0 1 1 2 3
29 0 0 1 3 3
32 I 0 0 1 1 5
38 I 0 0 0 1 6
49 Experiment terminated; tumours weighed.
Tumour weights (g.) : 40 18
34 11
25 10
19 0
TABLE V.-Two Experiment8 Showing the Effect of two Eth,ylene pho8phoramide8
(Compound II and Triethylenepho8phoramide) on the derived Walker Tunwur.
These substances produce a similar inhibitory effect on the original
Walker careiriosarcoma to triethylene melamine (Fig. I and Table I),
but have only a small retardiRg effect on the derived tumour.
Control. Treated.
Compound II (2
-0 mg./kg.)-
Number of animals 10 10
Treatment None 8 dosescommencing
4th day
Day telmiinated 13 13
Number surviving 10 10
Tumour weights (g.) 27 18 25 11
23 16 24 7
25 13 18 4
21 5 16 4
18 0 14 3
T.E.P.A. (2
- 0 mg./kg.)-
Number of animals 10 10
Treatment None 6 dosescommencing
5th day
Day terminated 10 10
Number surviving 10 10
Tumour weights (g.) 39 20 22 11
30 20 18 8
23 19 13 3
23 17 13 3
21 6 12 0- 5
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related to the presence of reactive ethyleneimino-groups rather than to general
molecular pattem.
DISCUSSION.
The conversion of a tumour normaRy sensitive to a drug into one which is
refractory, is of particular interest in relation to the further study of the mode
of action of chemotherapeutic agents; investigation of such phenomena may
contribute to a better understanding of the behaviour of malignant tumours in
man, and help to explain the general lack of correlation between human and
experimental tumours in their response to chemical inhibitors. In the few cases
of human malignant disease showing an initial favourable response to chemo-
therapy, the development of resistance seems so far, to be inevitable.
The results described in this paper appear to be the first account ofthe experi-
mental production of resistance in a sohd tumour in the rat, and the first of its
kind in ainy species relating to this categofy of chemical iinbibitor whose action is
apparently related to its high chemical reactivity. As was mentioned earlier,
the development of mouse leukaemia resistant to fohc acid analogues is wen
known and there has been a recent report that the Mouse Sarcoma 180, whicb is
moderately inbibited by 6-mercaptopurine, rapidly develops some resistance
to this compound (Clarke, Philips, Stemberg, Stock, Elion and Hitchings, 1953).
On the-whole, solid rat and mouse tumours appear to be relatively resistant
to chemical inhibitors, although the response of different tumours to the same
drug varies widely. Not often does the arrest of growth extend to all tumours
in an adequate group of experimental animals, in spite of the administration
of dose levels of near lethal magnitude (Suguira and, Stock, 1952a, 1952b). It
appears that rat tumours are moresusceptible than those ofthe mouse to trie-thy-
lene melamine, for complete regression has been obtained in nearly 100 per cent
,of animals with the Jensen rat sarcoma, Sarcoma R39 and the Flexner JobliDg
carcinoma (Suguira and Stock, 1952b). It is generally agreed that the longer
initiation of treatment is delayed, the less chance thei-e is of total regression.
-The action of triethylene melamine on the Walker carcinosarcoma is striking
-even when treatment is delayed for aslong as 5 days afterimplantation, by which
time the tumour is actively growing. In the present series of experiments
regression occurrecl in every animal and usuaRy little or no palpable material
-remained at the site of the implant. This confirms the work ofHendry, Homer,
Rose andWalpole(1951) and Peczenik(1952), whohowever, commencedtreatment
24 hr. after transplantation of the Walker tumour into Wistar rats. Curiously,
Suguira and Stock (1952b) were less successful with this tumour in Wistar rats,
.obtaining inhibition ofgrowth in 70 per cent ofanimals withday oldimplants and
regression in only 20 per cent when treatment was delayed for 7 days. The
complete inbibition ofthis tumour in our animals firstsuggested that a demonstra-
tion of the development of a resistant variety might be feasible. The results
clearly show that in effectively 4H animals the inhibitory effect is only temporary
and that growth subsequently occurred irrespective of the duration oftreatment,
even though this may be continued for several weeks instead of the usual 7-10
days. In either case thesuppression ofgrowth continued for upwards of 2 weeks
before renewal of activity could be detected. When administration of &-ug
began 24 hr. after implantation of the tumour and no growth occurred at an
,during the peri'od for which it was given, tumours subsequently developed asWALKER CARCINOSARCOMA RESISTANCE TO TRIETHYLENE MELAMINE 343
usual 2-3 weeks affer discontinuation of treatment in 9/10 animals. The derived
tumour on which most of the work has been carried out, was selected at random
from a group of tumours growing subsequent to one short course of treatment
applied to the original Walker tumour. The resistance it displayed has remained
essentially unchanged by further exposure to the drug. The tumour has since
been transmitted over 50 times witbout interposed treatment and tests have not
revealed any increase in sensitivity during this time. The resistance is thus
considered to be a stable and permanent change. Another member of a group
of tumours similarly derived from the original Walker carcinosarcoma has also
been shown topossesscomparableresistance to furthertreatment. It isreasonable
to suppose that the same will apply to all such tumours. A noticeable difference
between the original Walker and the derived tumours is the more rapidgrowth of
the latter in untreated animals.
The growth of tumours after a latent period followino, a short course of treat-
ment with triethylene melamine, must be due to the survival of a small number
of cells which are naturally resistant to the drug. The fact that this sequence of
events is not changed by the continued administration of triethylene melamine
to animals bearing implants of the original Walker tumour, suggests that the
resistance of the residual cells is maximal at the outset. Additional support for
this view emerges from the failure to enhance the resistance by further exposure
to the drug. How far mutagenic effects of the ethyleneimine may be concerned
remains to be investigated, but the fact that such a bigli proportioD of inhibited
tumours ultimately grow seems to make this factor less likely. The resistant
tumour has also been shown to be refractory to two other ethyleneimines (Com-
pounds II and III) at dose levels which completely inhibit the original Walker
carcinosarcoma. Thus resistance to triethylene melamine confers resistance to
a diethyleneimine, and this may be true of active ethyleneimines in general.
How far the same statement may apply to other kinds of chemical inhibitors
active against the ordinary Walker tumour is being investigated.
It is interesting that the Walker tumour should be so sensitive to triethylene
melamine, whilst two other tumours which have been tested in the same strain of
animal (a mammary adenocarcinoma and the lymphosarcoma referred to in the
text) were only little affected by the same treatment. Crossley, Allison, Wainio
and Muenzen (1951) studied the effect of triethylene melamine on a sarcoma
(231) in the King A rat. They reported that a dose of 0-1-0-2 mg./kg. daily
produced severe toxic symptoms and no tumour regressions were obtained under
these circumstances; 0-2 mg./kg. twice daily was lethal to these animals. With
smaller doses, e.g., 0-025 mg./kg. they were able to obtain complete regression
in from 50-75 per cent of animals. From their results it appears that. tumours
not inhibited by the drug treatment were able to grow at rates not very different
from those in unbreated apimals. Crossley, Allison and Muenzen (1952) also
reported the effect ofthe same drug on theFlexner-Jobling carcinoma in Sprague-
Dawley rats, and found complete regression in 70 per cent of all treated animals
witb none in control series. Regressions were stated to occur with doses ranging
from 0-016-0-046 mg./kg. twice daily, without evidence of toxic effects. Doses
of 0-23 mg./kg./day in 4 divided doses caused regression in all animals breated
not later than 8 days after transplantation. The cured animals showed no
recurrence up to I year after treatment. The authors comment that this strain
of rat was less sensitive to triethylene melamine than the King A variety.344 H. JACKSON
Suguira and Stock (1952b) used 0-25 mg./kg. of the triazine without undue toxic
effects. Treatment of 7-day old transplants of the FlexnerJobhng careinoma-
with this dose rate for 7 days produced regressions in 90 per cent of animals in
1 to 2 weeks. There was no reappearance of tumours during the next 3 months,
which was taken to indicate complete cure. A similar course of treatment
applied to 7 day old tumours of the Sarcoma R 39 resulted in their complete
destruction in 1 to 2 weeks after the first iniectioD.
The American strain of Wistar rat used in the present work showed httle
evidence oftoxic effects at adailydoselevel of0-2 mg./kg. oftriethylene melamine.
apart from l'oss ofappetite and weight. This latter may in turn hinder thegrowth
of the resistant Walker tumour and the other tumours mentioned. Not only
different kinds of tumour but various strains of rat vary in their susceptibihty
totriethylene melamine ; thegrowth of an occasional tumour in animals bearino, a
neoplasm susceptible to the drug, may be connected with some unsuspected
ability of the host animal to dispose of the administered compound. It appears
reasonable to suppose that ethyleneimino-compounds as a whole owe their
anti-tumouractivitytothesehighlyreactive groups, so that itisdifficulttoconceive
a protective mechanism possessed by some cefls but not by the great majority
in a tumour. It is equally difficult to imagine a high degree of susceptibility
in one variety ofneoplasm and indifference in another kind to chemical inhibitors
hke triethyleneimino-phospboramide (III), which is highly soluble in water and
hkely to diffuse with ease into cells. Then too, there is the fact which has been
estabhshed on many occasions, that the susceptibility of sensitive tumours to
these drugs diminishes markedly with the age (i.e., size) of the tumour. It is
hoped that a study of the mechanism by which the resistant Walker tumour is
derived from the original variety and an investigation of the reason for the insus-
ceptibihty of the formee tumour may throw light on these interesting and impor-
tant phenomena.
Only preliminary cytological studies have as yet been carried out. Inhibited
nodules from the Walker carcinosarcoma treated with triethylene melamine,
24 hr. after the conclusion of a course of treatment show intact tumour cells.
No mitotic figures were seen. Estimation ofthe mitotic index ofthe original and
derived forms, 48 hr. after the administration of the last of 2 doses of the same
drug reveals that the growth rates of the two tumours are similarly depressed.
The drug would therefore, appear to be exerting a cytotoxic effect on the resistant
form, although the overall growth of this tumour is not much hindered by such
treatment. A comparative study of the cytological effects ofethyleneimines on
these tumours is continuing.
SUMMARY.
1. Administration oftriethylene melaniine to animals bearing 24 hr. implants of the Walker carcinosarcoma, causes complete inhibition of tumour growth. Actively growing tumours (4-5 days old) with the same treatment first regress and then remain inhibited.
2. Inhibited tumour nodules subsequently grow after a latent period of 2-3
weeks in 70-90 per cent of animals. This happens irrespective of the duration
of treatment with theethyleneirnine, eventhough this may be continuedthrough-
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3. One of these tumours, selected at random, was resistant to further treat-
ments; there was no build-up of resistance with successive courses of the drug.
4. This resistant tumour, maintained routinely for over 12 months, has shown
no tendency to recover its sensitivity to triethylene melamine.
5. Cross-resistance of a similar order of magnitude is shown by this derived
tumour to two other ethyleneimines.
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